Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$25.00 USD

25.00
13,322,532

+0.16 (0.64%)

Updated Sep 17, 2025 04:00 PM ET

Pre-Market: $25.38 +0.38 (1.52%) 9:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $155.56, marking a +0.2% move from the previous day.

Zacks Equity Research

Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback

by Zacks Equity Research

Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.

Zacks Equity Research

Company News for Apr 12, 2023

by Zacks Equity Research

Companies in The News Are: MRNA, COIN, NVDA, DVN

Zacks Equity Research

Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RSP

Zacks Equity Research

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag

by Zacks Equity Research

The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.

Zacks Equity Research

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $154.61 in the latest trading session, marking a -1.22% move from the prior day.

Zacks Equity Research

Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

The Zacks Analyst Blog Highlights Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy

by Zacks Equity Research

Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Walt Disney, Marathon Petroleum & Moderna

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Marathon Petroleum Corporation (MPC), and Moderna, Inc. (MRNA).

Zacks Equity Research

Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $148.80 in the latest trading session, marking a +1.28% move from the prior day.

Zacks Equity Research

Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

by Zacks Equity Research

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

Zacks Equity Research

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Zacks Equity Research

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $149.42, moving +0.84% from the previous trading session.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Zacks Equity Research

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $151.78 in the latest trading session, marking a +1.46% move from the prior day.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Zacks Equity Research

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

by Zacks Equity Research

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Zacks Equity Research

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $138.29 in the latest trading session, marking a +0.68% move from the prior day.

Zacks Equity Research

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH